ASCENTAGE PHARMA GROUP INTERNATIONAL

Contributing Author

Recent Articles by ASCENTAGE PHARMA GROUP INTERNATIONAL

Dec-08	ASH 2025 Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment AAPG GlobeNewswire
Dec-08	ASH 2025 Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% AAPG GlobeNewswire
Dec-08	ASH 2025 Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP AAPG GlobeNewswire
Dec-07	ASH 2025 Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Exposed Patients with Myeloid Malignances AAPG GlobeNewswire
Dec-06	Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting AAPG GlobeNewswire
Dec-04	Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA AAPG GlobeNewswire
Dec-01	Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 AAPG GlobeNewswire
Nov-24	Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy AAPG GlobeNewswire
Nov-19	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 AAPG GlobeNewswire
Nov-03	Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025 AAPG GlobeNewswire
Nov-03	Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025 AAPG GlobeNewswire
Oct-29	Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 AAPG GlobeNewswire
Oct-07	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025 AAPG GlobeNewswire
Aug-25	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025 AAPG GlobeNewswire
Aug-20	Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates AAPG GlobeNewswire
Aug-17	Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA AAPG GlobeNewswire
Aug-07	Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 AAPG GlobeNewswire
Aug-01	Ascentage Pharma to Participate in Evercore China Biotech Summit AAPG GlobeNewswire
Jul-23	Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025 AAPG GlobeNewswire
Jul-17	Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement AAPG GlobeNewswire
Jul-14	Ascentage Pharma Announces Pricing of Top-Up Placement AAPG GlobeNewswire
Jul-14	Ascentage Pharma Announces Proposed Top-Up Placement AAPG GlobeNewswire
Jul-10	Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL AAPG GlobeNewswire
Jul-07	Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance AAPG GlobeNewswire
Jun-15	EHA 2025 Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL AAPG GlobeNewswire
Jun-09	Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress AAPG GlobeNewswire
Jun-02	Live from ASCO 2025 Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report AAPG GlobeNewswire
Jun-02	Live from ASCO 2025 Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors AAPG GlobeNewswire
May-22	Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 AAPG GlobeNewswire

ASCENTAGE PHARMA GROUP INTERNATIONAL

Recent Articles by ASCENTAGE PHARMA GROUP INTERNATIONAL

Upgrade your FINVIZ experience